WKN DE: A42EH4 / ISIN: US51255A2015

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV		Knock-Outs
Historisch			Analysen

Kurse + Charts + Realtime
Kurs + Chart
Chart (groß)
Times + Sales
Chartvergleich
Börsenplätze
Realtime Push
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Aktion
Portfolio
Watchlist

Lakewood-Amedex Biotherapeutics Times and Sales (NAS)

Zeit	Kurs	Umsatz (Stk)	Umsatz grafisch
Times and Sales Zur Zeit stehen keine Daten zur Verfügung

Kursrückgang	Kursanstieg	keine Kursänderung
(Balkenlänge beschreibt das Umsatzvolumen)

Nachrichten zu Lakewood-Amedex Biotherapeutics Inc Registered Shs

25.08.26

EQS-News: Lakewood-Amedex Biotherapeutics Becomes a B2i Digital Featured Company

Analysen zu Lakewood-Amedex Biotherapeutics Inc Registered Shs

Weitere Meldungen

04:32		Singapore yards chase profit from Europe’s offshore wind push
04:00		Should Investors Buy the Meta Platforms Dip?
03:15		Constellation, Vistra, and GE Vernova Ranked From Worst to First for the AI Power Boom
03:13		Ukraine Gets Starlink Speeds Back as Elon Musk Says Offensive Drone Use Was Never Allowed
02:55		Sydney’s new international airport opens to passengers
02:34		1 Red Flag That Keeps Me From Buying AMD Stock
02:30		Rocket Lab Just Postponed Its Neutron Launch. Again.
02:27		Gas supply cut from Indonesia accounts for less than 2% of Singapore’s daily gas demand: EMA
02:27		Gas supply cut from Indonesia accounts for less than 2% of Singapore’s daily gas demand: EMA
02:17		Audi to Build Factory in Georgia, Trump Says
02:02		Is the AI Bubble About to Burst? Plus, Apple Bets on Doorbells.
02:00		Co-operate to avoid being hostage to geopolitics, Australia tells ‘middle powers’
02:00		Co-operate to avoid being hostage to geopolitics, Australia tells ‘middle powers’
02:00		SpaceX’s $1 Trillion Revenue Ambition: Can Elon Musk Deliver?
02:00		Is Now a Good Time to Buy Lockheed Martin?
01:51		Nigeria: Tinubu launches reelection bid amid economic woes
01:50		Should You Ignore the SpaceX Hype and Buy Rocket Lab Instead?
01:00		Jemperli (dostarlimab) data show 76% of patients with MSI-H/dMMR locally advanced rectal cancer achieved a complete response
01:00		Forget the FDA Delay: 3 Reasons Exelixis Is Still a Buy
00:52		Booking vs. Chewy: Do Pet Treats or Plane Tickets Make for a Better Stock in 2026?
00:41		Is Berkshire Bending the Rules With Bending Spoons?
00:32		Advance Auto Parts vs. Etsy: Which Consumer Stock Is a Better Buy in 2026?
00:30		Stock-Split Watch: Is Palantir Next?
24.10.26		Booking vs. Five Below: Is the Travel Giant or Specialty Retailer the Better Stock to Buy in 2026?
24.10.26		Netflix Stock Has Always Overcome the Odds. Has It Finally Hit a Wall?
24.10.26		Before You Buy the Vanguard S&P 500 ETF, There's 1 Sneaky Risk Investors Should Know
24.10.26		Here's How Many Shares of Apple Stock You'd Need for $100 in Yearly Dividends
24.10.26		GE Vernova Stock Fell 11% in a Day. Here's What I Think It Could Be Worth by 2030.
24.10.26		Booking vs. GameStop: Is Travel or Collectibles the Better Value Creator in Stocks?
24.10.26		Elon Musk Just Gave Fantastic News for Nvidia Investors
24.10.26		Could Buying XRP Today Set You Up for Life?
24.10.26		Alibaba vs. Booking: Which Travel Provider Stock Is a Better Buy in 2026?
24.10.26		Ukraine: Starlink satellite speeds restored to normal
24.10.26		The Nasdaq Just Had Its Worst Day in 4 Months. Here's the Level That Would Signal a Correction, and What History Says Investors Can Do About It.
24.10.26		Oklo Is Down 61% This Year Despite a Real Technical Milestone. Here's the Disconnect Between the Stock and the Science.
24.10.26		Blackstone: 3 Key Takeaways for Long-Term Investors
24.10.26		Realty Income Stock Climbs Back as Treasury Yields Retreat, Yet Challenges Persist
24.10.26		Vertex Pharmaceuticals Gets 96% of Product Sales From Treatments for 1 Disease. Here's Why That's About to Change.
24.10.26		Elon Musk Is ‘Okay With Being Disliked’ — and He Knows Exactly Where His $985 Billion Fortune Is Going
24.10.26		Union Pacific Corporation: 3 Key Takeaways for Long-Term Investors
24.10.26		Advance Auto Parts vs. Booking Holdings: Which Consumer Stock Is a Better Buy in 2026?
24.10.26		Top Blockchains Continue to See Rapid Growth in AI Agent Payments. This Is the 1 Crypto You Need to Buy Right Now.
24.10.26		XRP Price Faces Downside Risk Despite Rising ETF Inflows and RLUSD Growth
24.10.26		Advance Auto Parts vs. Dick's Sporting Goods: Are Consumers Focusing on Car Repair or Exercise More in 2026?
24.10.26		5 of the Fastest-Growing Stocks in the Market
24.10.26		Down Roughly 50% From Its Highs, Is Netflix Stock Finally a Buy?
24.10.26		Is Nike Still a Growth Stock? Here's the Answer.
24.10.26		Broadcom vs. Dell Technologies: Which Stock Is AI Powering to Be a Better Buy in 2026?
24.10.26		Airbnb vs. Chewy: Do Pets or Places Power One Stock More than the Other?
24.10.26		Bloom Energy Raised Its 2026 Forecast for the Third Time. Is the Stock a Buy More Than a Third Below Its Record?

1 | Weiter

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Weitere Aktien: Gores a Neovacs Sinda Kioxia ADS Alia Mentis

Kontakt - Impressum - Werbung - Barrierefreiheit

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2026 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 81% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	25.10.2026 04:42
Kaufwert:	EUR
	Hinzufügen Speichern

Lakewood-Amedex Biotherapeutics Aktie

WKN DE: A42EH4 / ISIN: US51255A2015

Lakewood-Amedex Biotherapeutics Times and Sales (NAS)

Times and Sales

Nachrichten zu Lakewood-Amedex Biotherapeutics Inc Registered Shs

Analysen zu Lakewood-Amedex Biotherapeutics Inc Registered Shs

Weitere Meldungen